Drugs / nivasorexant
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05254548 | Feb → Apr 2022 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04753164 | Feb 2021 → Mar 2022 | binge eating disorder | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nivasorexant | “Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in...” PMID 37800597 ↗ Oct 2023 |
| Known as | ACT-539313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04753164 ↗ |
| Modality | Small molecule | — CHEMBL3892369 ↗ |
| Route | Oral | “taken orally” NCT04753164 ↗ |